Patent Ductus Arteriosus Clinical Trial
Official title:
Clinical Profile of Neonates Diagnosed by Echocardiography as Having Patent Ductus Arteriousus in Assiut University Hospital for Children
The study aims to evaluate the clinical presentation and course of PDA diagnosed at neonatal period in the neonatology unit of Assiut University Hospital for Children.
One of the most common cardiovascular problems that prematurely born infants experience early in life is patent ductus arteriosus (PDA). The ductus arteriosus is a blood vessel that connects the two major arteries, namely the aorta and the pulmonary artery, and is essential in maintaining circulation in fetal life. After the baby is born and the fetal circulation changes to adult circulation, the ductus arteriosus functionally closes between 18 and 24 hours of life (1 ). The arterial duct is a fetal blood vessel that is programmed to close shortly after birth. If the vessel remains patent beyond 3 months of life (a persistently patent arterial duct) it can result in volume loading of the left heart and should be closed either surgically or by a catheter-based procedure. A patent arterial duct is common in the newborn, particularly premature infants, and can contribute to persistent respiratory problems. (2) Historical estimates have placed the incidence of isolated PDA at approximately 0.05% of all live births. Isolated PDA accounts for 5% to 10% of congenital heart defects (3) number most likely represents the prevalence of a "symptomatic" PDA-that is, one that results in evidence of increased pulmonary blood flow, left heart volume overload, elevated PA pressure, murmur, etc. With the advent of color Doppler echocardiography, the incidental recognition of asymptomatic "silent" ductus has become more common. Some have estimated the prevalence of silent PDA among children and adults to be up to 0.5%, far more common than the "symptomatic" PDA (4). However, in babies born prematurely, the ductus arteriosus often fails to close spontaneously and leads to a number of morbidities. it has been shown that in infants born with a birth weight of <1000 g, the ductus arteriosus remains open in 66% of infants beyond the first week of life. In the extreme premature population born at 24 weeks of gestation, only 13% of infants are found to have their ductus closed by the end of the first week (5).This makes PDA an important issue from the clinical management perspective in the first few days of life in preterm infants. It is associated with a number of comorbidities such as necrotising enterocolitis (NEC), bronchopulmonary dysplasia and intraventricular haemorrhage (IVH) (6-7). The management controversy has mainly focused on when to treat and with what to treat. To increase the complexity of m atters, these two aspects of PDA management are not mutually exclusive, with the modality of treatment often being dictated by the timing of treatment. There have been a large number of published studies, meta-analyses and editorials focusing on different aspects of management.(8-9)Regarding the timing of treatment, prophylactic therapy has gradually fallen out of favor and neonatal units have shifted towards a more conservative approach by treating only the clinically and echocardiographically (ECHO) significant PDA (10).However, the big dilemma that still persists among neonatologists is what to use as the primary modality of treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04986839 -
PAIR (Paracetamol and Ibuprofen Research) Pilot Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT03648437 -
Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus
|
Phase 1 | |
Completed |
NCT04126512 -
Timing of Surgical PDA Ligation and Neonatal Outcomes
|
||
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Completed |
NCT00217191 -
Ibuprofen and Renal Function in Premature Infants
|
Phase 4 | |
Not yet recruiting |
NCT02894970 -
A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation
|
N/A | |
Completed |
NCT02621528 -
Lifetech CeraFlex™ Post-Market Surveillance Study
|
N/A | |
Completed |
NCT03551600 -
Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
|
||
Terminated |
NCT03982342 -
Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants
|
N/A | |
Completed |
NCT01479218 -
Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus
|
N/A | |
Completed |
NCT00795990 -
Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants
|
N/A | |
Terminated |
NCT00802685 -
Timing of PDA Closure and Respiratory Outcome in Premature Infants
|
N/A | |
Withdrawn |
NCT00554307 -
Brain, Gut and Kidney Blood Flow During Medical Closure of PDA
|
N/A | |
Completed |
NCT03723889 -
Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed
|
||
Recruiting |
NCT04397913 -
Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA
|
||
Completed |
NCT02750228 -
PDA Post NICU Discharge
|
||
Recruiting |
NCT02220270 -
Hyperion™ International Registry Trial
|
N/A | |
Completed |
NCT01593163 -
Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus
|
Phase 3 | |
Recruiting |
NCT06298344 -
The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease
|
Early Phase 1 | |
Completed |
NCT03277768 -
Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus.
|